Skip to Content
VirusesViruses
  • Review
  • Open Access

17 June 2022

12 Pages

Cardiac Complications of COVID-19 in Low-Risk Patients

,
,
and
1
Department of Medicine, Faculty of Medicine, Imperial College London, London SW7 2AD, UK
2
King’s College London BHF Centre, The Rayne Institute, St Thomas’ Hospital, London SE1 7EH, UK
3
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Post-COVID Syndrome

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has resulted in over 6 million deaths and significant morbidity across the globe. Alongside common respiratory symptoms, COVID-19 is associated with a variety of cardiovascular complications in the acute and post-acute phases of infection. The suggested pathophysiological mechanisms that underlie these complications include direct viral infection of the myocardium via the angiotensin-converting enzyme 2 (ACE2) protein and a cytokine release syndrome that results in indirect inflammatory damage to the heart. Patients with pre-existing cardiovascular disease and co-morbidities are generally more susceptible to the cardiac manifestations of COVID-19. However, studies have identified a variety of complications in low-risk individuals, including young adults and children. Myocarditis and paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS) are among the adverse events reported in the acute phase of infection. Furthermore, patients have reported cardiac symptoms persisting beyond the acute phase in post-COVID syndrome. This review summarises the acute and chronic cardiac consequences of COVID-19 in low-risk patients, explores the pathophysiology behind them, and discusses new predictive factors for poor outcomes.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.